Triccas JA[au] - Search Results

Year	Number of Results
1994	1
1995	2
1996	2
1997	1
1998	3
1999	1
2000	2
2001	5
2002	3
2003	2
2004	4
2005	3
2006	4
2007	5
2008	3
2009	6
2010	6
2011	4
2012	5
2013	6
2014	4
2015	3
2016	10
2017	3
2018	7
2019	5
2020	2
2021	10
2022	14
2023	2

1

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Khoury DS, et al. Among authors: triccas ja. Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17. Nat Med. 2021. PMID: 34002089

2

New standards for precision medicine in TB management.

Triccas JA, McLachlan AJ. Triccas JA, et al. Int J Tuberc Lung Dis. 2022 Jun 1;26(6):481-482. doi: 10.5588/ijtld.22.0222. Int J Tuberc Lung Dis. 2022. PMID: 35650696 No abstract available.

3

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.

Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA, Khoury DS, Davenport MP. Cromer D, et al. Among authors: triccas ja. Lancet Microbe. 2022 Jan;3(1):e52-e61. doi: 10.1016/S2666-5247(21)00267-6. Epub 2021 Nov 15. Lancet Microbe. 2022. PMID: 34806056 Free PMC article.

4

Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics.

Enriquez AB, Izzo A, Miller SM, Stewart EL, Mahon RN, Frank DJ, Evans JT, Rengarajan J, Triccas JA. Enriquez AB, et al. Among authors: triccas ja. Front Immunol. 2021 Oct 25;12:740117. doi: 10.3389/fimmu.2021.740117. eCollection 2021. Front Immunol. 2021. PMID: 34759923 Free PMC article. Review.

5

The generation of T-cell memory to protect against tuberculosis.

Counoupas C, Triccas JA. Counoupas C, et al. Among authors: triccas ja. Immunol Cell Biol. 2019 Aug;97(7):656-663. doi: 10.1111/imcb.12275. Epub 2019 Jun 12. Immunol Cell Biol. 2019. PMID: 31127962 Review.

6

New tuberculosis drug leads from naturally occurring compounds.

Quan D, Nagalingam G, Payne R, Triccas JA. Quan D, et al. Among authors: triccas ja. Int J Infect Dis. 2017 Mar;56:212-220. doi: 10.1016/j.ijid.2016.12.024. Epub 2017 Jan 3. Int J Infect Dis. 2017. PMID: 28062229 Free article. Review.

7

Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity.

Stewart E, Triccas JA, Petrovsky N. Stewart E, et al. Among authors: triccas ja. Microorganisms. 2019 Aug 12;7(8):255. doi: 10.3390/microorganisms7080255. Microorganisms. 2019. PMID: 31409028 Free PMC article. Review.

8

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame.

Triccas JA, Kint J, Wurm FM. Triccas JA, et al. NPJ Vaccines. 2022 Aug 2;7(1):89. doi: 10.1038/s41541-022-00507-8. NPJ Vaccines. 2022. PMID: 35918346 Free PMC article. No abstract available.

9

Deciphering protective immunity against tuberculosis: implications for vaccine development.

Counoupas C, Triccas JA, Britton WJ. Counoupas C, et al. Among authors: triccas ja. Expert Rev Vaccines. 2019 Apr;18(4):353-364. doi: 10.1080/14760584.2019.1585246. Epub 2019 Mar 4. Expert Rev Vaccines. 2019. PMID: 30793629 Review.

10

Novel vaccination approaches to prevent tuberculosis in children.

Triccas JA, Counoupas C. Triccas JA, et al. Pneumonia (Nathan). 2016 Nov 24;8:18. doi: 10.1186/s41479-016-0020-z. eCollection 2016. Pneumonia (Nathan). 2016. PMID: 28702297 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results